TGFB1 and myeloid sarcoma: On top of this, Rollnik et al. [28] illuminated that the expression level of TGF- β1 had declined in MS patients’ sera compared with the control group and Ishikawa et al. [29] confirmed that TGF-β1 was able to improve clinical EAE and inhibit relapse phase in them.